The holiday period included Genmab’s discontinuation of acasunlimab.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
Nenocorilant features among the latest industry projects newly into phase 1.
The private ADC company is being wound down.
Two new PD-(L)1 x VEGF projects have entered the clinic.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
